Bridge City Capital LLC reduced its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 24.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 172,146 shares of the company's stock after selling 57,050 shares during the period. Pacira BioSciences makes up approximately 1.3% of Bridge City Capital LLC's portfolio, making the stock its 27th biggest position. Bridge City Capital LLC owned about 0.37% of Pacira BioSciences worth $4,278,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently bought and sold shares of the company. Renaissance Technologies LLC grew its position in Pacira BioSciences by 0.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,992,601 shares of the company's stock valued at $37,541,000 after acquiring an additional 13,604 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Pacira BioSciences by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,091,970 shares of the company's stock worth $20,578,000 after acquiring an additional 5,071 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Pacira BioSciences in the fourth quarter worth $20,266,000. Nuveen Asset Management LLC increased its position in shares of Pacira BioSciences by 109.9% during the fourth quarter. Nuveen Asset Management LLC now owns 625,917 shares of the company's stock worth $11,792,000 after acquiring an additional 327,754 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Pacira BioSciences by 30.8% in the fourth quarter. Northern Trust Corp now owns 616,891 shares of the company's stock valued at $11,622,000 after acquiring an additional 145,205 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company's stock.
Pacira BioSciences Stock Performance
Pacira BioSciences stock traded up $0.11 during mid-day trading on Thursday, reaching $24.45. 1,033,861 shares of the company were exchanged, compared to its average volume of 973,674. The firm has a market cap of $1.13 billion, a PE ratio of -12.04 and a beta of 0.52. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The firm's 50-day simple moving average is $25.57 and its two-hundred day simple moving average is $23.48. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $29.95.
Insider Transactions at Pacira BioSciences
In other Pacira BioSciences news, SVP Lauren Riker sold 5,578 shares of Pacira BioSciences stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total value of $146,199.38. Following the sale, the senior vice president now owns 59,564 shares of the company's stock, valued at approximately $1,561,172.44. The trade was a 8.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.40% of the company's stock.
Analysts Set New Price Targets
Several research firms have recently issued reports on PCRX. Needham & Company LLC lowered their price objective on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Barclays upped their price target on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th. HC Wainwright raised their price objective on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a report on Tuesday, April 8th. Finally, Wall Street Zen raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $26.44.
Read Our Latest Stock Analysis on Pacira BioSciences
About Pacira BioSciences
(
Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Featured Articles
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
